Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Tipranavir in preparation of cancer treatment drug for killing tumor stem cells and tumor cells

A technology of tumor stem cells and tumor cells, which is applied in the field of preparing cancer therapeutic drugs that kill tumor stem cells and tumor cells, and can solve the problems of unreported literature reports and unused anti-tumor, etc., so as to improve the effect and improve the quality of life

Active Publication Date: 2021-01-26
SHENZHEN UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, at present, the application of Tipranavir in the preparation of drugs for the treatment of tumor stem cells and tumor cells has not been reported in the literature, and has not been used in anti-tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Tipranavir in preparation of cancer treatment drug for killing tumor stem cells and tumor cells
  • Application of Tipranavir in preparation of cancer treatment drug for killing tumor stem cells and tumor cells
  • Application of Tipranavir in preparation of cancer treatment drug for killing tumor stem cells and tumor cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1: Tipranavir can effectively kill human gastric cancer stem cells at a low concentration, and it is time- and concentration-dependent.

[0052] Two lines of gastric cancer stem cells (denoted as GCSC1 and GCSC2) derived from different gastric cancer patients were taken, and the cell concentrations were both (1×10 5 cells / mL, 100μl), inoculated in 96-well plate, three replicate wells in each group, treated GCSC1 with different concentrations of Tipranavir (0uM, 0.5uM, 1.0uM, 2.5uM, 5.0uM, 10uM, 20uM, 40uM, 100uM) And GCSC2 cells 24hr, 48hr, 72hr, DMSO as a control. CCK-8 was added to measure the absorbance value (A450) at a wavelength of 450 nm, and the cell growth curves of each group were drawn. Detect the killing effect of Tipranavir on gastric cancer stem cells (GCSC1 and GCSC2), and calculate its IC 50 , see the result figure 1 ( figure 1 , cell viability cell activity; concentration concentration).

[0053] The results showed that Tipranavir could eff...

Embodiment 2

[0054] Example 2: The effect of Tipranavir on killing gastric cancer stem cells is significantly better than that of the existing first-line drug combined with 5-FU and cisplatin.

[0055] Two lines of gastric cancer stem cells (denoted as GCSC1 and GCSC2) derived from different gastric cancer patients (1×10 5 cells / mL, 100 μl) were inoculated in 96-well plates, and each group had three replicate wells, and GCSC1 and GCSC2 cells were treated with Tipranavir (10uM) and 5-FU+cisplatin (5-FU: 2.5μM; cisplatin: 4μM) for 72hr, respectively, DMSO served as a control. CCK-8 was added to measure the absorbance value (A450) at a wavelength of 450 nm, and the cell growth curves of each group were drawn. Comparison of the killing effects of Tipranavir and 5-FU+cisplatin on gastric cancer stem cells (GCSC1 and GCSC2). see results figure 2 ( figure 2 , cell viability cell activity).

[0056] The results showed that the effect of Tipranavir on killing gastric cancer stem cells was si...

Embodiment 3

[0057] Example 3: Tipranavir can effectively kill gastric cancer cells, and its effect is also significantly better than the combination of 5-FU and cisplatin, and has no toxic side effects on normal gastric epithelial cells, while the combination of 5-FU and cisplatin has no effect on normal gastric epithelial cells. Cell toxicity.

[0058] Four gastric cancer cell lines (AGS, HGC-27, MGC-803, BGC-823) and normal gastric epithelial cell line (GES-1) (1×10 5 cells / mL, 100 μl) were inoculated in 96-well plates, and each group had three replicate wells, and the cells of each strain were treated with Tipranavir (10uM) and 5-FU+cisplatin (5-FU: 2.5μM; cisplatin: 4μM) for 72hr, DMSO as comparison. CCK-8 was added to measure the absorbance value (A450) at a wavelength of 450 nm, and the cell growth curves of each group were drawn. To compare the killing effects and side effects of Tipranavir and 5-FU+cisplatin on gastric cancer cells (AGS, HGC-27, MGC-803, BGC-823) and normal gast...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of Tipranavir in preparation of a cancer treatment drug for killing tumor stem cells and tumor cells, and relates to the technical field of medicines. The inventionfurther discloses a cancer treatment drug. The drug can kill the tumor stem cells and the tumor cells; the drug takes the Tipranavir as a main active component and contains a pharmaceutically acceptable carrier. The invention provides the Tipranavir for the first time, and the Tipranavir can be used for preparing the anti-cancer drug for killing the tumor stem cells and the tumor cells; the anti-gastric cancer effect of the Tipranavir is obviously better than that of an existing gastric cancer first-line treatment drug (5-FU and cisplatin are combined); the Tipranavir has no obvious toxic side effect and the toxic side effect is obviously smaller than that of the gastric cancer first-line treatment drug (5-FU and cisplatin are combined); a novel drug and scheme are provided for tumor treatment of targeted tumor stem cells and healing of tumors; and the Tipranavir has important meanings on improvement of the tumor treatment effect and improvement of the living quality of patients.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of Tipranavir in the preparation of cancer therapeutic drugs for killing tumor stem cells and tumor cells. Background technique [0002] Malignant tumors are diseases with high morbidity and high mortality that seriously endanger human health. For example, gastric cancer (GC) is the most common malignant tumor of the digestive system, its incidence rate ranks fifth among all malignant tumors in the world, and its mortality rate ranks third among the causes of malignant tumors. my country is a high-incidence area of ​​gastric cancer, with high morbidity and mortality, both ranking second in malignant tumors. The principle of gastric cancer treatment is comprehensive treatment based on surgical treatment. In my country, the early diagnosis rate of gastric cancer is still relatively low. Most patients are diagnosed with advanced tumors and lose the chance of surgi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4433A61K31/337A61P35/00
CPCA61K31/4433A61K31/337A61P35/00A61K2300/00
Inventor 付利熊继先
Owner SHENZHEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com